Position paper of the Polish expert group on the use of pitavastatin in the treatment of lipid disorders in Poland endorsed by the Polish Lipid Association

Maciej Banach; Stanisław Surma; Agnieszka Kapłon-Cieślicka; Przemysław Mitkowski; Grzegorz Dzida; Tomasz Tomasik; Agnieszka Mastalerz-Migas

eISSN: 2450-4459
ISSN: 2450-3517

Lekarz POZ

Current issue Archive Manuscripts accepted About the journal Supplements Abstracting and indexing Subscription Contact Instructions for authors

Editorial System

Submit your Manuscript

6/2023
vol. 9

Send email

Copy url:

abstract:

Position paper of the Polish expert group on the use of pitavastatin in the treatment of lipid disorders in Poland endorsed by the Polish Lipid Association

Maciej Banach

^{1, 2, 3, 4}

,

Stanisław Surma

⁵

,

Agnieszka Kapłon-Cieślicka

⁶

,

Przemysław Mitkowski

⁷

,

Grzegorz Dzida

⁸

,

Tomasz Tomasik

⁹

,

Agnieszka Mastalerz-Migas

¹⁰

Zakład Kardiologii Prewencyjnej i Lipidologii, Uniwersytet Medyczny w Łodzi
Ciccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Stany Zjednoczone
Ośrodek Badań Sercowo-Naczyniowych, Uniwersytet Zielonogórski, Zielona Góra
Klinika Kardiologii i Wad Wrodzonych Dorosłych, Instytut Centrum Zdrowia Matki Polki w Łodzi
Klinika Chorób Wewnętrznych i Farmakologii Klinicznej, Śląski Uniwersytet Medyczny w Katowicach
I Katedra i Klinika Kardiologii, Warszawski Uniwersytet Medyczny, Warszawa
I Katedra Kardiologii, Uniwersytet Medyczny w Poznaniu
Katedra i Klinika Chorób Wewnętrznych, Uniwersytet Medyczny w Lublinie
Katedra Medycyny Rodzinnej, Collegium Medicum, Uniwersytet Jagielloński w Krakowie
Katedra i Zakład Medycyny Rodzinnej, Uniwersytet Medyczny we Wrocławiu

Online publish date: 2023/12/17

View full text Get citation

Lipid disorders, primarily hypercholesterolemia, are the most common cardiovascular risk factor in Poland (3/4 of people). The LDL cholesterol (LDL-C) serum level is the basic lipid parameter that should be measured to determine cardiovascular risk and determines the aim and target of lipid-lowering treatment. Lipid-lowering treatment improves cardiovascular prognosis and prolongs life in both primary and secondary cardiovascular prevention. Despite the availability of effective lipid-lowering drugs and solid data on their beneficial effects, the level of LDL-C control is highly insufficient. This is related, among other things, to physician inertia and patients’ fear of side effects. The development of lipidology has made drugs available with a good safety profile and enabling personalization of therapy. Pitavastatin, the third most potent lipid-lowering statin, is characterized by a lower risk of muscle complications and new cases of diabetes due to its different metabolism. Thus, pitavastatin is a very good therapeutic option in patients at high risk of diabetes or with existing diabetes, and in patients at the cardiovascular risk. This expert opinion presents information on the place and possibility of using pitavastatin in the treatment of lipid disorders.

keywords:

Position paper of the Polish expert group on the use of pitavastatin in the treatment of lipid disorders in Poland endorsed by the Polish Lipid Association

Maciej Banach 1, 2, 3, 4 , Stanisław Surma 5 , Agnieszka Kapłon-Cieślicka 6 , Przemysław Mitkowski 7 , Grzegorz Dzida 8 , Tomasz Tomasik 9 , Agnieszka Mastalerz-Migas 10

lipid disorders, therapy personalization, pitavastatin

Maciej Banach

^{1, 2, 3, 4}

,

Stanisław Surma

⁵

,

Agnieszka Kapłon-Cieślicka

⁶

,

Przemysław Mitkowski

⁷

,

Grzegorz Dzida

⁸

,

Tomasz Tomasik

⁹

,

Agnieszka Mastalerz-Migas

¹⁰